# Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant

> **NCT01687270** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 40 (actual)

## Conditions studied

- Recurrent Chronic Hepatitis C Virus
- Post Liver Transplant

## Interventions

- **DRUG:** Sofosbuvir
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT01687270
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-12
- **Final completion:** 2014-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01687270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01687270, "Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01687270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*